Oramed Pharmaceuticals (ORMP) Competitors $2.22 +0.02 (+0.91%) Closing price 04:00 PM EasternExtended Trading$2.23 +0.01 (+0.45%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ORMP vs. CTMX, ALDX, BNTC, TNXP, FDMT, AMRN, ZYBT, CADL, CAPR, and LRMRShould you be buying Oramed Pharmaceuticals stock or one of its competitors? The main competitors of Oramed Pharmaceuticals include CytomX Therapeutics (CTMX), Aldeyra Therapeutics (ALDX), Benitec Biopharma (BNTC), Tonix Pharmaceuticals (TNXP), 4D Molecular Therapeutics (FDMT), Amarin (AMRN), Zhengye Biotechnology (ZYBT), Candel Therapeutics (CADL), Capricor Therapeutics (CAPR), and Larimar Therapeutics (LRMR). These companies are all part of the "pharmaceutical products" industry. Oramed Pharmaceuticals vs. Its Competitors CytomX Therapeutics Aldeyra Therapeutics Benitec Biopharma Tonix Pharmaceuticals 4D Molecular Therapeutics Amarin Zhengye Biotechnology Candel Therapeutics Capricor Therapeutics Larimar Therapeutics Oramed Pharmaceuticals (NASDAQ:ORMP) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability. Do institutionals & insiders believe in ORMP or CTMX? 12.7% of Oramed Pharmaceuticals shares are held by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are held by institutional investors. 17.8% of Oramed Pharmaceuticals shares are held by insiders. Comparatively, 6.6% of CytomX Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more volatility & risk, ORMP or CTMX? Oramed Pharmaceuticals has a beta of 1.69, indicating that its share price is 69% more volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 2.18, indicating that its share price is 118% more volatile than the S&P 500. Do analysts prefer ORMP or CTMX? CytomX Therapeutics has a consensus price target of $5.75, indicating a potential upside of 173.81%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe CytomX Therapeutics is more favorable than Oramed Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00CytomX Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ORMP or CTMX more profitable? CytomX Therapeutics has a net margin of 34.04% compared to Oramed Pharmaceuticals' net margin of 0.00%. CytomX Therapeutics' return on equity of 158.70% beat Oramed Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Oramed PharmaceuticalsN/A -19.37% -18.28% CytomX Therapeutics 34.04%158.70%36.04% Does the media favor ORMP or CTMX? In the previous week, CytomX Therapeutics had 2 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 3 mentions for CytomX Therapeutics and 1 mentions for Oramed Pharmaceuticals. Oramed Pharmaceuticals' average media sentiment score of 1.05 beat CytomX Therapeutics' score of 0.51 indicating that Oramed Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oramed Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CytomX Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, ORMP or CTMX? CytomX Therapeutics has higher revenue and earnings than Oramed Pharmaceuticals. Oramed Pharmaceuticals is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOramed Pharmaceuticals$1.34M67.93-$19.06M-$0.35-6.34CytomX Therapeutics$138.10M2.51$31.87M$0.563.75 SummaryCytomX Therapeutics beats Oramed Pharmaceuticals on 13 of the 16 factors compared between the two stocks. Get Oramed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORMP vs. The Competition Export to ExcelMetricOramed PharmaceuticalsMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$91.02M$10.78B$5.76B$9.91BDividend YieldN/A1.84%6.66%4.49%P/E Ratio-6.3421.6883.0126.65Price / Sales67.9330.42503.05163.66Price / CashN/A25.1325.7028.92Price / Book0.593.4110.796.52Net Income-$19.06M$211.94M$3.29B$266.21M7 Day Performance0.91%-3.31%0.01%-0.76%1 Month Performance6.22%7.76%7.06%3.83%1 Year Performance-6.72%-8.09%50.09%24.39% Oramed Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORMPOramed Pharmaceuticals1.1415 of 5 stars$2.22+0.9%N/A-8.7%$90.21M$1.34M-6.3410Positive NewsCTMXCytomX Therapeutics4.2487 of 5 stars$2.00-5.7%$5.75+187.5%+89.3%$349.61M$138.10M3.57170ALDXAldeyra Therapeutics2.4993 of 5 stars$5.77-0.7%$9.50+64.6%+0.7%$347.99MN/A-6.7910News CoverageBNTCBenitec Biopharma1.6686 of 5 stars$13.21+1.7%$26.00+96.8%+54.9%$340.99M$80K-8.7520News CoverageGap DownTNXPTonix Pharmaceuticals3.0154 of 5 stars$34.59-8.9%$70.00+102.4%+65.0%$332.93M$10.09M-0.8850Gap DownFDMT4D Molecular Therapeutics2.7822 of 5 stars$6.74-4.9%$30.40+351.0%-56.1%$331.12M$40K-1.91120News CoverageGap UpAMRNAmarin0.6407 of 5 stars$15.39-3.7%$12.00-22.0%+20.2%$330.90M$228.61M-4.19360ZYBTZhengye BiotechnologyN/A$8.00+14.6%N/AN/A$329.22M$25.53M0.00278News CoverageCADLCandel Therapeutics2.0368 of 5 stars$5.71-4.0%$22.00+285.3%-19.0%$326.63M$120K-8.2860News CoverageAnalyst DowngradeCAPRCapricor Therapeutics2.9009 of 5 stars$6.60-7.0%$22.56+241.8%+43.7%$324.59M$22.27M-4.02101LRMRLarimar Therapeutics3.1184 of 5 stars$3.72-4.9%$18.43+395.4%-43.1%$323.66MN/A-2.3830Positive News Related Companies and Tools Related Companies CytomX Therapeutics Competitors Aldeyra Therapeutics Competitors Benitec Biopharma Competitors Tonix Pharmaceuticals Competitors 4D Molecular Therapeutics Competitors Amarin Competitors Zhengye Biotechnology Competitors Candel Therapeutics Competitors Capricor Therapeutics Competitors Larimar Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORMP) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredTrump’s national nightmare is hereWashington just added $1 trillion to the national debt in less than two months — an astonishing pace of spendi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oramed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oramed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ORMP Stock Alerts